期刊
MOLECULAR NEUROBIOLOGY
卷 52, 期 1, 页码 78-92出版社
SPRINGER
DOI: 10.1007/s12035-014-8845-z
关键词
Ceftriaxone; GLT-1; Astrocytes; MPP+; Neuroprotection
资金
- Science and Technology Planning Project of Guangdong Province [2012B050200003]
- Science and Technology Planning Project of Guangzhou [2013J4500018]
Ceftriaxone has been shown to attenuate the dopaminergic neuron death and alleviate behavioral disorders in Parkinson's disease models via upregulation of glutamate transporter-1 (GLT-1) and decreases in extracellular glutamate. However, details of how this neuroprotection occurs are uncertain. We hypothesized that cytoprotection by ceftriaxone in astrocytes exposed to 1-methyl-4-phenylpyridinium (MPP+) involves suppression of the NF-kappa B/JNK/c-Jun signaling pathway. Here, we observed a protective effect of ceftriaxone in primary astrocytes exposed to MPP+. Ceftriaxone enhanced glutamate uptake and promoted primary astrocyte viability after MPP+ exposure. Ceftriaxone enhances glutamate uptake via upregulation of GLT-1 in the plasma membrane, and alleviates MPP+-induced neurotoxicity via suppression of NF-kappa B/JNK/c-Jun signaling. Collectively, our data offer evidence that increased expression and function of GLT-1 are involved in the protective mechanism of ceftriaxone in astrocytes exposed to MPP+ in vitro, and we offer insight into the potential therapeutic role of ceftriaxone in treatment of Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据